Get the Stockscreener App
2.42
5.68%
0.13
After Hours:
2.48
0.06
+2.48%
Nkarta Inc stock is traded at $2.42, with a volume of 749.61K.
It is up +5.68% in the last 24 hours and up +7.08% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.29
Open:
$2.29
24h Volume:
749.61K
Relative Volume:
1.05
Market Cap:
$172.52M
Revenue:
-
Net Income/Loss:
$-104.08M
P/E Ratio:
-1.7201
EPS:
-1.4069
Net Cash Flow:
$-89.91M
1W Performance:
+4.76%
1M Performance:
+7.08%
6M Performance:
-7.98%
1Y Performance:
+41.52%
1-Day Range:
$2.26
$2.44
1-Week Range:
$2.13
$2.44
52-Week Range:
$1.63
$2.81
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.42 | 163.26M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Nkarta announces FDA agreement on outpatient dosing of NKX019 in autoimmune disease, expanding access to community rheumatology centers - marketscreener.com
Nkarta receives FDA agreement for outpatient NKX019 dosing - Investing.com
Nkarta Reports FDA Agreement on Outpatient Dosing of NKX019 - marketscreener.com
Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials - Stock Titan
CEO Moves: Will Nkarta Inc stock benefit from M A2026 Investor Takeaways & Technical Pattern Alert System - baoquankhu1.vn
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Aug PostEarnings: Is Nkarta Inc stock suitable for long term investing2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Nkarta to Participate in Needham Virtual Healthcare Conference - Bitget
Nkarta leaders to discuss autoimmune cell therapy at Needham event - Stock Titan
Ideas Watch: Does Nkarta Inc have declining or rising EPSGap Down & High Win Rate Trade Tips - baoquankhu1.vn
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Layoff Watch: What analysts say about Nkarta Inc stock2026 Technicals & Real-Time Buy Zone Alerts - baoquankhu1.vn
[EFFECT] Nkarta, Inc. SEC Filing - Stock Titan
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Nkarta (NASDAQ: NKTX) launches $100M ATM shelf via Stifel as sales agent - Stock Titan
NKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho - Defense World
NKTX PE Ratio & Valuation, Is NKTX Overvalued - Intellectia AI
Mizuho lowers Nkarta stock price target on sales ramp moderation - Investing.com
Mizuho lowers Nkarta stock price target on sales ramp moderation By Investing.com - Investing.com India
HC Wainwright Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX) - MarketBeat
Nkarta files $350M shelf offering, plans $100M ATM stock sale via Stifel - MSN
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
TD Cowen Maintains Nkarta(NKTX.US) With Buy Rating - Moomoo
Risk Hedge: Will Nkarta Inc stock go up in YEARPortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail
Nkarta Launches $100 Million At-the-Market Stock Offering - The Globe and Mail
Nkarta (NASDAQ:NKTX) Price Target Raised to $11.00 at Needham & Company LLC - Defense World
Nkarta, Inc. Files Form 8-K With SEC Detailing Company and Stock Information – March 25, 2026 - Minichart
NKTX (Nkarta) PB Ratio : 0.51 (As of Mar. 26, 2026) - GuruFocus
Nkarta (NASDAQ:NKTX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Stifel reiterates Nkarta stock rating on trial enrollment progress By Investing.com - Investing.com South Africa
Stifel reiterates Nkarta stock rating on trial enrollment progress - Investing.com
Nkarta launches $100M at-the-market equity program with Stifel - TradingView
Nkarta, Inc. 2025 Annual Report: Advancing Allogeneic CAR NK-Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aug Momentum: Should value investors consider Nkarta Inc2026 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Nkarta, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Nkarta (NASDAQ: NKTX) launches $100M at-the-market stock sale plan - Stock Titan
Nkarta Files $350 Million Mixed Shelf - marketscreener.com
Nkarta (NASDAQ: NKTX) launches $100M at-the-market program via $350M shelf - Stock Titan
Nkarta (NASDAQ:NKTX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Nkarta 2025 10-K: Net loss $104.1M, EPS $(1.41) - TradingView
[10-K] Nkarta, Inc. Files Annual Report - Stock Titan
Nkarta (NASDAQ: NKTX) reports 2025 loss and extends cash runway to 2029 - stocktitan.net
Nkarta reports fourth quarter and full year 2025 financial results and corporate highlights - MarketScreener
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights - The Globe and Mail
Nkarta (NKTX) to Release Earnings on Tuesday - Defense World
Trend Report: Is Nkarta Inc stock a buy or sell2026 Levels & Reliable Intraday Trade Plans - baoquankhu1.vn
Nkarta Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):